Tags

Type your tag names separated by a space and hit enter

CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Neurosci Lett 2008; 440(2):145-9NL

Abstract

Alzheimer's disease (AD) is the leading cause of dementia. Currently, no definitive diagnostic test for AD exists. An accurate, convenient and objective test to detect AD is urgently needed for efficient drug development and effective clinical use of emerging therapies. The aim of the present work is to investigate the usefulness of cerebrospinal fluid (CSF) beta-amyloid protein (Abeta1-42) and total tau protein (t-tau) analyses in the diagnosis of AD and whether apolipoprotein E (ApoE) epsilon4 allele is a factor for AD affecting Tunisian people. Abeta1-42 and t-tau levels were measured in CSF from AD patients (n=73), non-Alzheimer dementia (nAD, n=35) and healthy controls (HC, n=38) by sandwich enzyme-linked immunosorbent assay. Abeta1-42 levels were decreased and t-tau increased in AD patients. The combination of Abeta1-42 and t-tau at baseline yielded a sensitivity of 87.4% for detection of AD. The specificities were 97.3% for controls and 82.7% for other dementia. The ApoE epsilon4 allele frequency (29.5%) was significantly higher in the AD patients than in the nAD patients (17.1%) or in the control groups (9.5%). AD patients carrying ApoE epsilon4 allele had lower Abeta1-42 (p<0.001) levels than those without a epsilon4 allele. The combination of t-tau and Abeta1-42 is a robust and reliable assay that may be useful in discriminating cases at risk for AD such as ApoE epsilon4 allele carriers from nAD patients or from age-matched control subjects.

Authors+Show Affiliations

Department of Biochemistry, Faculty of Medicine of Sousse, Tunisia. dalifms@yahoo.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18555606

Citation

Smach, Mohamed Ali, et al. "CSF Beta-amyloid 1-42 and Tau in Tunisian Patients With Alzheimer's Disease: the Effect of APOE Epsilon4 Allele." Neuroscience Letters, vol. 440, no. 2, 2008, pp. 145-9.
Smach MA, Charfeddine B, Lammouchi T, et al. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele. Neurosci Lett. 2008;440(2):145-9.
Smach, M. A., Charfeddine, B., Lammouchi, T., Harrabi, I., Ben Othman, L., Dridi, H., ... Limem, K. (2008). CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele. Neuroscience Letters, 440(2), pp. 145-9. doi:10.1016/j.neulet.2008.05.076.
Smach MA, et al. CSF Beta-amyloid 1-42 and Tau in Tunisian Patients With Alzheimer's Disease: the Effect of APOE Epsilon4 Allele. Neurosci Lett. 2008 Aug 1;440(2):145-9. PubMed PMID: 18555606.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele. AU - Smach,Mohamed Ali, AU - Charfeddine,Bassem, AU - Lammouchi,Turkia, AU - Harrabi,Imed, AU - Ben Othman,Leila, AU - Dridi,Hedi, AU - Bennamou,Soufien, AU - Limem,Khalifa, Y1 - 2008/05/24/ PY - 2008/02/25/received PY - 2008/05/06/revised PY - 2008/05/21/accepted PY - 2008/6/17/pubmed PY - 2008/9/16/medline PY - 2008/6/17/entrez SP - 145 EP - 9 JF - Neuroscience letters JO - Neurosci. Lett. VL - 440 IS - 2 N2 - Alzheimer's disease (AD) is the leading cause of dementia. Currently, no definitive diagnostic test for AD exists. An accurate, convenient and objective test to detect AD is urgently needed for efficient drug development and effective clinical use of emerging therapies. The aim of the present work is to investigate the usefulness of cerebrospinal fluid (CSF) beta-amyloid protein (Abeta1-42) and total tau protein (t-tau) analyses in the diagnosis of AD and whether apolipoprotein E (ApoE) epsilon4 allele is a factor for AD affecting Tunisian people. Abeta1-42 and t-tau levels were measured in CSF from AD patients (n=73), non-Alzheimer dementia (nAD, n=35) and healthy controls (HC, n=38) by sandwich enzyme-linked immunosorbent assay. Abeta1-42 levels were decreased and t-tau increased in AD patients. The combination of Abeta1-42 and t-tau at baseline yielded a sensitivity of 87.4% for detection of AD. The specificities were 97.3% for controls and 82.7% for other dementia. The ApoE epsilon4 allele frequency (29.5%) was significantly higher in the AD patients than in the nAD patients (17.1%) or in the control groups (9.5%). AD patients carrying ApoE epsilon4 allele had lower Abeta1-42 (p<0.001) levels than those without a epsilon4 allele. The combination of t-tau and Abeta1-42 is a robust and reliable assay that may be useful in discriminating cases at risk for AD such as ApoE epsilon4 allele carriers from nAD patients or from age-matched control subjects. SN - 0304-3940 UR - https://www.unboundmedicine.com/medline/citation/18555606/CSF_beta_amyloid_1_42_and_tau_in_Tunisian_patients_with_Alzheimer's_disease:_the_effect_of_APOE_epsilon4_allele_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0304-3940(08)00739-8 DB - PRIME DP - Unbound Medicine ER -